title: Comparison of celecoxib metabolism and excretion in mouse, rabbit, dog, cynomolgus monkey and rhesus monkey.
abstract: 1. The metabolism and excretion of celecoxib, a specific cyclooxygenase 2 (COX-2) inhibitor, was investigated in mouse, rabbit, the EM (extensive) and PM (poor metabolizer) dog, and rhesus and cynomolgus monkey. 2. Some sex and species differences were evident in the disposition of celecoxib. After intravenous (i.v.) administration of [14C]celecoxib, the major route of excretion of radioactivity in all species studied was via the faeces: EM dog (80.0%), PM dog (83.4%), cynomolgus monkey (63.5%), rhesus monkey (83.1%). After oral administration, faeces were the primary route of excretion in rabbit (72.2%) and the male mouse (71.1%), with the remainder of the dose excreted in the urine. After oral administration of [14C]celecoxib to the female mouse, radioactivity was eliminated equally in urine (45.7%) and faeces (46.7%). 3. Biotransformation of celecoxib occurs primarily by oxidation of the aromatic methyl group to form a hydroxymethyl metabolite, which is further oxidized to the carboxylic acid analogue. 4. An additional phase I metabolite (phenyl ring hydroxylation) and a glucuronide conjugate of the carboxylic acid metabolite was produced by rabbit. 5. The major excretion product in urine and faeces of mouse, rabbit, dog and monkey was the carboxylic acid metabolite of celecoxib.
authors.affiliation: Pharmacokinetics, Bioanalytical & Radiochemistry, G.D. Searle & Co, Skokie, IL, USA. Susan.K.Paulson@monsanto.com
authors.forename: S K
authors.initials: SK
authors.lastname: Paulson
authors.forename: J Y
authors.initials: JY
authors.lastname: Zhang
authors.forename: S M
authors.initials: SM
authors.lastname: Jessen
authors.forename: Y
authors.initials: Y
authors.lastname: Lawal
authors.forename: N W
authors.initials: NW
authors.lastname: Liu
authors.forename: C M
authors.initials: CM
authors.lastname: Dudkowski
authors.forename: Y F
authors.initials: YF
authors.lastname: Wang
authors.forename: M
authors.initials: M
authors.lastname: Chang
authors.forename: D
authors.initials: D
authors.lastname: Yang
authors.forename: J W
authors.initials: JW
authors.lastname: Findlay
authors.forename: M A
authors.initials: MA
authors.lastname: Berge
authors.forename: C S
authors.initials: CS
authors.lastname: Markos
authors.forename: A P
authors.initials: AP
authors.lastname: Breau
authors.forename: J D
authors.initials: JD
authors.lastname: Hribar
authors.forename: J
authors.initials: J
authors.lastname: Yuan
mesh_terms: D000818:Animals; D000068579:Celecoxib; D002851:Chromatography, High Pressure Liquid; D016861:Cyclooxygenase Inhibitors / Q000493:pharmacokinetics*; D004285:Dogs; D005243:Feces / Q000737:chemistry; D005260:Female; D008252:Macaca fascicularis; D008253:Macaca mulatta; D008297:Male; D013058:Mass Spectrometry; D051379:Mice; D011720:Pyrazoles; D011817:Rabbits; D013045:Species Specificity; D013449:Sulfonamides / Q000493:pharmacokinetics*
chemical_list: D016861:Cyclooxygenase Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib